- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01915511
Idiopatisk lungefibrose og interstitiel lungesygdom Prospektive udfaldsregister (IPF/ILD-PRO)
Idiopatisk lungefibrose prospektive udfald (IPF-PRO) og kronisk fibroserende interstitiel lungesygdom med progressive fænotype prospektive udfald (IPF-PRO/ILD-PRO) register
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
Studieoversigt
Status
Detaljeret beskrivelse
This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Rosalia Blanco
- Telefonnummer: 919-660-0890
- E-mail: rosalia.blanco@duke.edu
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- Rekruttering
- University of Alabama - Birmingham
-
Ledende efterforsker:
- Tejaswini Kulkarni, MD
-
Kontakt:
- Arnissa Hopson
- Telefonnummer: 205-934-1657
- E-mail: agoggins@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, Forenede Stater, 85721
- Rekruttering
- University of Arizona
-
Ledende efterforsker:
- Sally A Suliman, MD
-
Kontakt:
- Daniel Castaneda-Beltran
- Telefonnummer: 602-827-2347
- E-mail: dcastanedabeltra@arizona.edu
-
-
California
-
Los Angeles, California, Forenede Stater, 90033
- Rekruttering
- University of Southern California
-
Kontakt:
- Lynn Fukusima
- E-mail: Lynn.Fukushima@med.usc.edu
-
Ledende efterforsker:
- Toby Maher, MD
-
Los Angeles, California, Forenede Stater, 90024
- Rekruttering
- University of California - Los Angeles
-
Ledende efterforsker:
- John Belperio, MD
-
Kontakt:
- Stephanie Roblero
- Telefonnummer: 310-627-2319
- E-mail: sroblero@mednet.ucla.edu
-
Stanford, California, Forenede Stater, 94305
- Rekruttering
- Stanford University
-
Ledende efterforsker:
- Rishi Raj, MD
-
Kontakt:
- Summer Zhu
- Telefonnummer: 650-724-5424
- E-mail: szhuye@stanford.edu
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Rekruttering
- University of Colorado
-
Ledende efterforsker:
- Joyce Lee, MD
-
Kontakt:
- Olivia Brohl
- Telefonnummer: 303-724-0641
- E-mail: Olivia.brohl@cuanschutz.edu
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06520
- Rekruttering
- Yale University
-
Ledende efterforsker:
- Mridu Gulati, MD
-
Kontakt:
- Maksym Minasyan
- Telefonnummer: 203-785-4177
- E-mail: maksym.minasyan@yale.edu
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32610-3175
- Rekruttering
- University of Florida
-
Kontakt:
- Lisbetty Lugo
- E-mail: lisbetty.lugo@medicine.ufl.edu
-
Ledende efterforsker:
- Diana Gomez Manjarres, MD
-
Tampa, Florida, Forenede Stater, 33606
- Rekruttering
- University of South Florida
-
Ledende efterforsker:
- Jose D Herazo-Maya, MD
-
Kontakt:
- Natasha Brown
- E-mail: nbrown@tgh.org
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University
-
Kontakt:
- Tracy Halabi
- Telefonnummer: 404-712-7458
- E-mail: tracy.halaby@emory.edu
-
Ledende efterforsker:
- Srihari Veeraraghavan, MD
-
Austell, Georgia, Forenede Stater, 30106
- Rekruttering
- Piedmont Healthcare
-
Ledende efterforsker:
- Amy Case, MD
-
Kontakt:
- Munachi (Muna) Iwotor
- Telefonnummer: 404-291-9062
- E-mail: munachi.iwotor@piedmont.org
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago
-
Ledende efterforsker:
- Mary Strek, MD
-
Kontakt:
- Vanita Patel
- E-mail: vpatel4@bsd.uchicago.edu
-
Evanston, Illinois, Forenede Stater, 60611
- Rekruttering
- Northwestern University
-
Kontakt:
- Phillip Cooper
- Telefonnummer: 312-503-0406
- E-mail: p-cooper@northwestern.edu
-
Ledende efterforsker:
- Bradford Bemiss, MD
-
Maywood, Illinois, Forenede Stater, 60153
- Rekruttering
- Loyola University Health System
-
Ledende efterforsker:
- Daniel Dilling, MD
-
Kontakt:
- Sloan White
- E-mail: swhite29@luc.edu
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Afsluttet
- University of Kansas
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- Rekruttering
- University of Kentucky
-
Ledende efterforsker:
- Girish Nair, MD
-
Kontakt:
- Kai Su
- Telefonnummer: 859-257-4501
- E-mail: kai.su@uky.edu
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70112
- Rekruttering
- Tulane University
-
Ledende efterforsker:
- Joe Lasky, MD
-
Kontakt:
- Sandy Ditta
- Telefonnummer: 504-988-4040
- E-mail: sditta@tulane.edu
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Aktiv, ikke rekrutterende
- University of Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Rekruttering
- Henry Ford Health
-
Kontakt:
- Deepti Naidu
- Telefonnummer: 313-916-8732
- E-mail: dnaidu1@HFHS.ORG
-
Ledende efterforsker:
- Asif Abdul Hameed, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55455
- Rekruttering
- University of Minnesota
-
Kontakt:
- Mandi DeGrote
- Telefonnummer: 612-626-7609
- E-mail: carl1032@umn.edu
-
Ledende efterforsker:
- Hyum Kim, MD
-
-
Mississippi
-
Jackson, Mississippi, Forenede Stater, 39216
- Rekruttering
- University of Mississippi Medical Center
-
Ledende efterforsker:
- Kimberly Dobbs, MD
-
Kontakt:
- Leadeashia Brackett
- Telefonnummer: 601-496-7814
- E-mail: lbrackett@umc.edu
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University
-
Ledende efterforsker:
- Tonya Russell, MD
-
Kontakt:
- Mona Noroozi
- Telefonnummer: 314-362-3705
- E-mail: mnoroozi@wustl.edu
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Rekruttering
- Weill Medical College of Cornell University
-
Ledende efterforsker:
- Kerri Aronson, MD
-
Kontakt:
- Alicia Morris
- Telefonnummer: 646-692-2741
- E-mail: ajm2017@med.cornell.edu
-
New York, New York, Forenede Stater, 10016
- Aktiv, ikke rekrutterende
- NYU Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27514
- Rekruttering
- UNC Chapel Hill
-
Ledende efterforsker:
- Jason Lobo, MD
-
Kontakt:
- Jackson Pettee
- E-mail: Jackson_pettee@med.unc.edu
-
Durham, North Carolina, Forenede Stater, 27705
- Rekruttering
- Duke University
-
Ledende efterforsker:
- Lake Morrison, MD
-
Kontakt:
- Lauren Gray
- Telefonnummer: 919-684-7317
- E-mail: lauren.gray@duke.edu
-
Greensboro, North Carolina, Forenede Stater, 27403
- Rekruttering
- Pulmonix LLC
-
Ledende efterforsker:
- Murali Ramaswamy, MD
-
Kontakt:
- Mei Zheng
- Telefonnummer: 336-522-8870
- E-mail: mei.zheng@pulmonix.com
-
Wilmington, North Carolina, Forenede Stater, 28401
- Afsluttet
- PMG Research
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Rekruttering
- Wake Forest Baptist Health
-
Kontakt:
- Bob Hmieleski
- Telefonnummer: 336-713-8550
- E-mail: bhmieles@wakehealth.edu
-
Ledende efterforsker:
- Andrew Namen, MD
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45267
- Aktiv, ikke rekrutterende
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Cleveland Clinic
-
Ledende efterforsker:
- Brian Southern, MD
-
Kontakt:
- Ron Wehrmann
- Telefonnummer: 2164450574
- E-mail: wehrmar@ccf.org
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- The Ohio State University
-
Kontakt:
- Benjamin Hood
- E-mail: benjamin.hood2@osumc.edu
-
Ledende efterforsker:
- John Odackal
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- Rekruttering
- University of Oklahoma
-
Ledende efterforsker:
- Jad Kebbe, MD
-
Kontakt:
- Maria Mason
- Telefonnummer: 405-271-6173
- E-mail: maria-l-mason@ouhsc.edu
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97220
- Rekruttering
- Oregon Clinic
-
Ledende efterforsker:
- David Hotchkin, MD
-
Kontakt:
- Meg Day
- Telefonnummer: 503-963-3182
- E-mail: mday@orclinic.com
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forenede Stater, 17033
- Rekruttering
- Penn State College of Medicine - Hershey
-
Ledende efterforsker:
- Rebecca Bascom, MD
-
Kontakt:
- Tim Sheehan
- Telefonnummer: 717-531-2925
- E-mail: tsheehan@pennstatehealth.psu.edu
-
Philadelphia, Pennsylvania, Forenede Stater, 19140
- Rekruttering
- Temple University
-
Ledende efterforsker:
- Rachel Criner, MD
-
Kontakt:
- Luis Cardenas-Osorio
- Telefonnummer: 215-707-3311
- E-mail: Luis.Cardenas-Osorio@tuhs.temple.edu
-
Philadelphia, Pennsylvania, Forenede Stater, 19144
- Rekruttering
- Thomas Jefferson University
-
Ledende efterforsker:
- Ross Summer, MD
-
Kontakt:
- Ramya Talluri, BSN, RN
- E-mail: RamyaPriya.Talluri@jefferson.edu
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Rekruttering
- Medical University of South Carolina
-
Ledende efterforsker:
- Timothy Whelan, MD
-
Kontakt:
- Audra Wiser
- E-mail: wisera@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Rekruttering
- Vanderbilt University
-
Kontakt:
- James Del Greco
- Telefonnummer: 615-343-7068
- E-mail: james.del.greco@vumc.org
-
Ledende efterforsker:
- Justin Hewlett, MD
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75235
- Rekruttering
- University of Texas Southwestern
-
Ledende efterforsker:
- John Fitzgerald, MD
-
Kontakt:
- Meagan Galvan
- Telefonnummer: 214-645-6489
- E-mail: Maegan.Galvan@UTSouthwestern.edu
-
Dallas, Texas, Forenede Stater, 75246
- Rekruttering
- Baylor University Medical Center at Dallas
-
Ledende efterforsker:
- Yolanda Mageto, MD
-
Kontakt:
- Mary Alayo
- Telefonnummer: 214-820-6276
- E-mail: Mary.Alayo@BSWHealth.org
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Baylor College of Medicine
-
Ledende efterforsker:
- Ivan Rosas, MD
-
Kontakt:
- Maria C Perea
- E-mail: Maria.Perea@bcm.edu
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Houston Methodist Lung Center
-
Ledende efterforsker:
- Zeenat Safdar, MD
-
Kontakt:
- Laura Valecillos Loukidis
- Telefonnummer: 346-238-4637
- E-mail: lvvalecillosloukidis@houstonmethodist.org
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- The University of Texas Health Science Center At Houston
-
Ledende efterforsker:
- Rodeo Abrencillo, MD
-
Kontakt:
- Beverly Rios
- Telefonnummer: 713-486-6152
- E-mail: Beverly.Rios@uth.tmc.edu
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84108
- Rekruttering
- University of Utah
-
Kontakt:
- Adeline Langer
- Telefonnummer: 801-581-5811
- E-mail: adeline.langer@hsc.utah.edu
-
Ledende efterforsker:
- Mary Beth Langer, MD
-
Salt Lake City, Utah, Forenede Stater, 84111
- Rekruttering
- Intermountain Health
-
Kontakt:
- Aisha Skowyra
- Telefonnummer: 801-507-2439
- E-mail: Aisha.fairclough@imail.org
-
Ledende efterforsker:
- Erin Blackstock, MD
-
-
Vermont
-
Colchester, Vermont, Forenede Stater, 05446
- Aktiv, ikke rekrutterende
- University of Vermont Lung Center
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- Aktiv, ikke rekrutterende
- University from Virginia
-
Falls Church, Virginia, Forenede Stater, 22042-3307
- Rekruttering
- Inova Health Care Services
-
Kontakt:
- Taruni Maganti
- Telefonnummer: 703-776-3230
- E-mail: Taruni.Maganti@inova.org
-
Ledende efterforsker:
- Jared Wilkinson, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Aktiv, ikke rekrutterende
- The Medical College of Wisconsin
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.
Beskrivelse
Inclusion Criteria:
-
Willing and able to provide informed consent
-
Established a new diagnosis (within 12 months) of IPF by the enrolling center.
-
Age 21 years or older, or
-
Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:
-
Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.
-
Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):
- decline in FVC % predicted (% pred) based on ≥10% relative decline
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
- decline in DLCO % pred based on≥ 10% relative decline
- worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.
-
The relative decline for FVC % predicted is calculated using the formula:
Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.
The relative decline for DLCO % predicted is calculated using the formula:
Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening
Exclusion Criteria:
- Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
- Currently listed for lung transplantation at the time of enrollment
- Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
- For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry |
|
Subjects with a non-IPF ILD diagnosis
Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype |
|
New Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Data on natural history of IPF & non-IPF chronic fibrosing ILD
Tidsramme: End of Study (3 years after last patient will be enrolled)
|
Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Tidsramme: End of Study (3 years after last patient will be enrolled)
|
Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD |
End of Study (3 years after last patient will be enrolled)
|
|
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
Tidsramme: End of Study (3 years after last patient will be enrolled)
|
Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL). |
End of Study (3 years after last patient will be enrolled)
|
|
Blood samples for future research.
Tidsramme: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions. |
End of Study (3 years after last patient will be enrolled)
|
|
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Tidsramme: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal HRCT images for future research |
End of Study (3 years after last patient will be enrolled)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Data on management practices compared to existing guidelines.
Tidsramme: End of Study (3 years after last patient will be enrolled)
|
Compare disease-specific management practices with existing guidelines. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on center-specific practices on outcomes.
Tidsramme: End of Study (3 years after last patient will be enrolled)
|
Determine the influence of center-specific practices on patient outcomes. |
End of Study (3 years after last patient will be enrolled)
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Scott Palmer, MD, Duke Clinical Research Institute, Duke University
Publikationer og nyttige links
Generelle publikationer
- Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry investigators. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Ann Am Thorac Soc. 2022 Jun;19(6):981-990. doi: 10.1513/AnnalsATS.202105-589OC.
- Kim HJ, Snyder LD, Neely ML, Hellkamp AS, Hotchkin DL, Morrison LD, Bender S, Leonard TB, Culver DA; IPF-PRO Registry investigators. Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry. Lung. 2022 Feb;200(1):21-29. doi: 10.1007/s00408-021-00506-x. Epub 2022 Jan 7.
- de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2022 Jan 7;23(1):3. doi: 10.1186/s12931-021-01921-7.
- Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4.
- Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, Hartmann N, Palmer SM, Leonard TB; IPF-PRO Registry principal investigators as follows. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020 Nov;17(11):1413-1423. doi: 10.1513/AnnalsATS.201912-880OC.
- Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA; IPF-PRO Registry Investigators. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest. 2020 Jun;157(6):1522-1530. doi: 10.1016/j.chest.2019.12.041. Epub 2020 Jan 29.
- O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB; IPF-PRO Registry investigators. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. Chest. 2020 May;157(5):1188-1198. doi: 10.1016/j.chest.2019.11.042. Epub 2020 Jan 15.
- Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z.
- Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; IPF-PRO Registry investigators. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9.
- O'Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, Conoscenti CS. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res. 2016 Jan 11;3(1):e000108. doi: 10.1136/bmjresp-2015-000108. eCollection 2016.
- Swaminathan AC, Weber JM, Todd JL, Palmer SM, Neely ML, Whelan TP, Kim GHJ, Leonard TB, Goldin J. Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry. Respir Res. 2025 Feb 28;26(1):73. doi: 10.1186/s12931-025-03136-6.
- Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, Palmer SM, Todd JL; IPF-PRO Registry Investigators. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2025 Aug;168(2):415-422. doi: 10.1016/j.chest.2025.02.018. Epub 2025 Feb 26.
- Sack C, Wojdyla DM, MacMurdo MG, Gassett A, Kaufman JD, Raghu G, Redlich CA, Li P, Olson AL, Leonard TB, Todd JL, Neely ML, Snyder LD, Gulati M; IPF-PRO Registry investigators. Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Ann Am Thorac Soc. 2025 Mar;22(3):378-386. doi: 10.1513/AnnalsATS.202404-382OC.
- Wang L, Wu P, Liu Y, Patel DC, Leonard TB, Zhao H. Clustering-aided prediction of outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2024 Oct 23;25(1):383. doi: 10.1186/s12931-024-03015-6.
- Lobo LJ, Liu Y, Li P, Ramaswamy M, Swaminathan AC, Veeraraghavan S, Fan Y, Neely ML, Palmer SM, Olson AL; ILD-PRO Registry investigatorsdagger. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024 Sep 27;24(1):468. doi: 10.1186/s12890-024-03247-8.
- Summer R, Todd JL, Neely ML, Lobo LJ, Namen A, Newby LK, Shafazand S, Suliman S, Hesslinger C, Keller S, Leonard TB, Palmer SM, Ilkayeva O, Muehlbauer MJ, Newgard CB, Roman J. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2024 Jan 25;25(1):58. doi: 10.1186/s12931-023-02644-7.
- Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, Oldham JM, Raj R, White ES, Palmer SM. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Aug 24;24(1):209. doi: 10.1186/s12931-023-02503-5.
- Ruan P, Todd JL, Zhao H, Liu Y, Vinisko R, Soellner JF, Schmid R, Kaner RJ, Luckhardt TR, Neely ML, Noth I, Porteous M, Raj R, Safdar Z, Strek ME, Hesslinger C, Palmer SM, Leonard TB, Salisbury ML. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31;24(1):141. doi: 10.1186/s12931-023-02435-0.
- Menon AA, Gansen B, Mulder H, Neely ML, Papavasileiou P, Salisbury ML, Southern BD, Hesslinger C, Leonard TB, Meissner F, Todd JL. Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis. Respir Res. 2025 Oct 22;26(1):294. doi: 10.1186/s12931-025-03377-5.
- Shetty S, Swaminathan AC, Li P, Neely ML, Olson AL, Snyder LD; ILD-PRO Registry investigators. Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry. Lung. 2026 May 27;204(1):32. doi: 10.1007/s00408-026-00895-x.
- Swaminathan AC, Mulder H, Neely ML, Schmid R, Belperio JA, Patel NM, Palmer SM, Todd JL. Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis. Respir Res. 2026 Mar 25;27(1):196. doi: 10.1186/s12931-026-03641-2.
- Neely ML, Todd JL, Snyder LD, Li P, Olson AL; IPF-PRO Registry Investigators *. Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. CHEST Pulm. 2024 Dec 27;3(4):100133. doi: 10.1016/j.chpulm.2024.100133. eCollection 2025 Dec.
- MacMurdo MG, Wojdyla DM, Gassett A, Kaufman JD, Raghu G, Redlich CA, Patel DC, Neely ML, Snyder LD, Gulati M, Sack C; IPF-PRO Registry investigators. Short-term air pollution exposure and hospitalizations in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Ann Am Thorac Soc. 2026 Sep 12:aaoag285. doi: 10.1093/annalsats/aaoag285. Online ahead of print.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- Pro00046131
- 1199.174 (Anden identifikator: DCRI)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .